Table 1 Characteristics of all included patients
From: Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings
Variables | Plaques ( +) n = 121 (17.3%) | Plaques (-) n = 580 (82.7%) | P value |
|---|---|---|---|
Age (median, IQR) | 74 (70–78) | 72 (65–77) | < 0.001 |
Sex, Male | 112 (92.5%) | 313 (54.0%) | < 0.001 |
Smoking history | 111 (91.7%) | 342 (59.0%) | < 0.001 |
Preoperative CT findings | |||
Radiological emphysematous changes (GS ≥ 5 points) | 54 (44.6%) | 138 (23.8%) | < 0.001 |
Radiological IP findings | 39 (32.2%) | 115 (19.8%) | 0.004 |
Whole tumor size (mm) (median, IQR) | 21 (15–31) | 20 (14–28) | 0.024 |
Solid tumor size (mm) (median, IQR) | 19 (12–28) | 15 (10–25) | 0.013 |
SUVmax | 5.4 (2.4–13.0) | 2.6 (1.3–6.3) | < 0.001 |
Pulmonary function | |||
%VC (%) (median, IQR) | 95.9 (86.4–109.7) | 102.5 (89.7–113.8) | 0.010 |
FEV1/FVC (%) (median, IQR) | 75.8 (67.2–85.3) | 77.8 (71.6–85.6) | 0.007 |
Clinical stage | 0.561 | ||
IA1 | 24 (19.8%) | 153 (26.3%) | |
IA2 | 41 (33.9%) | 188 (32.4%) | |
IA3 | 22 (18.2%) | 92 (15.8%) | |
IB | 15 (12.4%) | 64 (11.0%) | |
IIA | 3 (2.5%) | 10 (1.7%) | |
IIB | 11 (9.1%) | 41 (7.1%) | |
IIIA | 5 (4.1%) | 25 (4.3%) | |
IIIB | 0 (0%) | 7 (1.2%) | |
Surgical procedure | 0.676 | ||
Wedge resection | 31 (25.6%) | 180 (31.0%) | |
Segmentectomy | 17 (14.1%) | 78 (13.4%) | |
Lobectomy | 71 (58.7%) | 315 (54.3%) | |
Pneumonectomy | 2 (1.7%) | 7 (1.2%) | |
Invasive characteristics | |||
LY | 14 (11.6%) | 57 (9.8%) | 0.569 |
V | 13 (10.7%) | 54 (9.3%) | 0.631 |
PL | 0.249 | ||
PL1 | 13 (10.7%) | 49 (8.5%) | |
PL2 | 3 (2.5%) | 14 (2.4%) | |
PL3 | 7 (5.8%) | 14 (2.4%) | |
Histology | < 0.001 | ||
Adenocarcinoma | 66 (54.5%) | 460 (79.3%) | |
Squamous cell carcinoma | 47 (38.8%) | 91 (15.7%) | |
Adenosquamous carcinoma | 2 (1.7%) | 14 (2.4%) | |
Sarcomatoid carcinoma | 1 (0.8%) | 6 (1.0%) | |
LCNEC | 4 (3.3%) | 7 (1.2%) | |
Lymphoepithelioma-like carcinoma | 1 (0.8%) | 1 (0.2%) | |
Mucoepidermoid carcinoma | 0 (0%) | 1 (0.2%) | |
Pathological stage | 0.021 | ||
0 | 5 (4.1%) | 49 (8.4%) | |
IA1 | 26 (21.5%) | 171 (29.5%) | |
IA2 | 24 (19.8%) | 113 (19.5%) | |
IA3 | 16 (13.2%) | 74 (12.8%) | |
IB | 20 (16.5%) | 76 (13.1%) | |
IIA | 5 (4.1%) | 8 (1.4%) | |
IIB | 10 (8.3%) | 50 (8.6%) | |
IIIA | 15 (12.4%) | 32 (5.5%) | |
IIIB | 0 (0%) | 7 (1.2%) | |
Recurrence | 28 (23.1%) | 104 (17.9%) | 0.192 |
Death from any cause | 37 (30.6%) | 91 (15.7%) | < 0.001 |
Death from lung cancer | 16 (13.2%) | 49 (8.5%) | 0.115 |
Death from respiratory disease | 12 (9.9%) | 21 (3.6%) | 0.007 |
Death from causes other than lung cancer and respiratory disease | 9 (7.4%) | 21 (3.6%) | 0.079 |